Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab: a cross-sectional study from the BioDay registry
| Autor: | Marlies de Graaf, Jart A F Oosterhaven, Marie L A Schuttelaar, Marjolein S. de Bruin-Weller, Angelique N Voorberg, Celeste Mirte Boesjes, Geertruida L E Romeijn, Lotte S. Spekhorst, Junfen Zhang |
|---|---|
| Přispěvatelé: | Public Health Research (PHR) |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
2019-20 coronavirus outbreak
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Cross-sectional study Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Eczema Dermatology Personal Satisfaction Antibodies Monoclonal Humanized Severity of Illness Index VALIDATION Dermatitis Atopic Treatment satisfaction 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine eczema control immune system diseases dupilumab otorhinolaryngologic diseases medicine Humans TOOL Registries treatment satisfaction questionnaire for medication skin and connective tissue diseases Atopic dermatitis 030203 arthritis & rheumatology business.industry recap of atopic eczema atopic dermatitis control test medicine.disease Dupilumab body regions Cross-Sectional Studies Treatment Outcome Patient Satisfaction business |
| Zdroj: | Journal of dermatological treatment, 33(4), 1986-1989. Taylor & Francis Ltd |
| ISSN: | 0954-6634 |
| Popis: | Background: Eczema control is a new construct to be measured in atopic dermatitis (AD).Objectives: Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks.Methods: Cross-sectional questionnaire study. Patients from the Dutch BioDay registry completed the Atopic Dermatitis Control Test (ADCT), Recap of Atopic Eczema (RECAP) and Treatment Satisfaction Questionnaire for Medication, Version II (TSQM v. II), along with other Patient Reported Outcome Measures (PROMs).Results: 104/157 patients responded (response rate 66.2%). Median ADCT score was 4 (interquartile range [IQR] 5); median RECAP score was 5 (IQR 6); median TSQM v.II global satisfaction score was 83.3 (IQR 25.0). According to the ADCT, 38.5-66.3% perceived their AD was 'in control', depending on the interpretability method used. Minimally clinically important difference (MCID) of >= 4 points for the DLQI and POEM was achieved respectively in N = 66 (84.6%) and N = 63 (78.8%) patients.Conclusion: When considering the favorable scores on other PROMs and the TSQM v. II, and comparing these to the relatively low percentage of patients perceiving control according to the ADCT, interpretability of eczema control still appears difficult. Treatment satisfaction in the studied cohort was high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|